ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Other Events

0

ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Other Events
Item 8.01. Other Events.

On November9, 2017, Adaptimmune Therapeutics plc (the “Company” or “Adaptimmune”) issued a press release announcing an oral presentation with updated data from its ongoing pilot study of NY-ESO SPEAR T-cells in synovial sarcoma and an overview of study design from a trial in progress poster for its ongoing study of NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma at the 2017 Connective Tissue Oncology Society (CTOS) annual meeting. The press release is furnished as Exhibit99.1 to this report and is incorporated by reference herein.

On November10, 2017, the Company issued a press release announcing the presentation of two trials in progress posters at the 2017 Society for Immunotherapy for Cancer (SITC) annual meeting. The trials in progress posters summarized the study designs for Adaptimmune’s ongoing clinical trials with MAGE-A4 SPEAR T-cells targeting multiple solid tumors and NY-ESO SPEAR T-cells with or without KEYTRUDA® (pembrolizumab) in multiple myeloma. The press release is furnished as Exhibit99.2 to this report and is incorporated by reference herein.

The information in Item 8.01 of this Form8-K (including the attached Exhibit99.1 and the attached Exhibit99.2) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”), or incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by the Company by specific reference in such a filing.

Item 8.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are furnished as part of this Report on Form8-K:

ExhibitNo.

DescriptionofExhibit

99.1

Press release concerning presentation of data at CTOS meeting dated November9, 2017

99.2

Press release concerning presentation of trials in progress posters at SITC meeting dated November10, 2017


Adaptimmune Therapeutics PLC Exhibit
EX-99.1 2 a17-26420_1ex99d1.htm EX-99.1 Exhibit 99.1     NY-ESO Data Presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting Confirm Potential of Adaptimmune’s SPEAR T-Cell Therapy   PHILADELPHIA,…
To view the full exhibit click here

About ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP)

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase their affinity to cancer-specific peptides, including its lead target peptides, NY-ESO-1 and MAGE-A10, in order to target and then destroy cancer cells in patients. The Company’s TCR therapeutic candidates are able to target intracellular, as well as extracellular cancer antigens. The TCRs consist of approximately two associated protein chains: the alpha and beta chains. Each of the chains has approximately two regions: a variable region and a constant region.

An ad to help with our costs